Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
Twitter Feed
-
This June, we are joining @WomenDeliver to celebrate power, progress & change in Vancouver! Attend our panel discussion on the issues facing women of child-bearing age who have an autoimmune disease (3 June, 9:00) https://t.co/xp0T7jOulX https://t.co/
— UCB News (@ucb_news) 17.05.2019 -
We will join more than 6,000 world leaders, influencers, advocates, academics, activists and journalists in Vancouver for the Women Deliver 2019 conference (3-6 June 2019). The world’s largest on gender equality and health, rights, and wellbeing and women
— UCB News (@ucb_news) 17.05.2019 -
#fragilityfractures affect 1 in 3 women over 50 worldwide – make sure you know about your risk of #osteoporosis. Speak to your healthcare professional to find out more. #NationalWomensHealthWeek https://t.co/qyaevIzizD
— UCB News (@ucb_news) 17.05.2019
